Table 2 Intracranial objective response and adverse events in the overall cohort.
Overall | Immunotherapy | Immunotherapy + radiotherapy | P.value | |
|---|---|---|---|---|
N = 138 | N = 99 | N = 39 | ||
Objective response rate, % (95% CI) | 58.5(47–69) | 49.1(35–63) | 75.9(56–90) | 0.034* |
Best overall response | ||||
CR | 11 | 7 (13.2%) | 4 (13.8%) | 1.00 |
PR | 37 | 19 (35.8%) | 18 (62.1%) | 0.04** |
SD | 28 | 24 (45.2%) | 4 (13.8%) | 0.09** |
PD | 6 | 3 (5.8%) | 3 (10.3%) | 0.66 |
Serious adverse events | ||||
Discontinuation of ICIs | 6 | 6 (6.1%) | 0 (0.0%) | 0.184 |
